Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) corrected previously released data from an interim analysis of a Phase 2 clinical trial of its cystic fibrosis treatments VX-809 and Kalydeco sending the stock price plummeting $9.38 to $55.47.